Martin G. Sanda

Dr. Martin G. Sanda


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
MSMartin G. Sanda
Martin G. Sanda
ZFZiding Feng
Ziding Feng
DHDavid H. Howard
David H. Howard
STScott A. Tomlins
Scott A. Tomlins
LSLori J. Sokoll
Lori J. Sokoll
STSamir Taneja
Samir Taneja
Ample evidence has shown survival benefits associated with treatment of intermediate- and high-risk, early-stage prostate cancer.1-4 Low specificity of tests for serum levels of prostate-specific antigen (PSA), however, has limited its utility for prostate cancer screening.5-7 Strategies are needed for detecting cancers with more aggressive features (Gleason score, ≥7) to enable survival benefits from treatment while limiting unnecessary biopsies and overdetection of indolent disease.

1 January 2018 in Journal of Urology
Verified
Journal Article
Closed access
DBDonna Berry
Donna Berry
FHFangxin Hong
Fangxin Hong
TBTraci M. Blonquist
Traci M. Blonquist
BHBarbara Halpenny
Barbara Halpenny
CFChristopher P. Filson
Christopher P. Filson
PSPrabhakara Somayaji
Prabhakara Somayaji
We evaluated the efficacy of the web based P3P (Personal Patient Profile-Prostate) decision aid vs usual care with regard to decisional conflict in men with localized prostate cancer. A randomized (1:1), controlled, parallel group, nonblinded trial was performed in 4 regions of the United States. Eligible men had clinically localized prostate cancer and an upcoming consultation, and they spoke and read English or Spanish. Participants answered questionnaires to report decision making stage, personal characteristics, concerns and preferences plus baseline symptoms and decisional conflict. A randomization algorithm allocated participants to receive tailored education and communication coaching, generic teaching sheets and external websites plus a 1-page summary to clinicians (intervention) or the links plus materials provided in clinic (usual care). Conflict outcomes and the number of consultations were measured at 1 month. Univariate and multivariable models were used to analyze outcomes. A total of 392 men were randomized, including 198 to intervention and 194 to usual care, of whom 152 and 153, respectively, returned 1-month outcomes. The mean ± SD 1-month decisional conflict scale (score range 0 to 100) was 10.9 ± 16.7 for intervention and 9.9 ± 18.0 for usual care. The multivariable model revealed significantly reduced conflict in the intervention group (-5.00, 95% CI -9.40--0.59). Other predictors of conflict included income, marital or partner status, decision status, number of consultations, clinical site and D'Amico risk classification. In this multicenter trial the decision aid significantly reduced decisional conflict. Other variables impacted conflict and modified the effect of the decision aid, notably risk classification, consultations and resources. P3P is an effective adjunct for shared decision making in men with localized prostate cancer.

17 April 2017 in The Prostate
Verified
Journal Article
Closed access
PDF file
KPKathryn L. Pellegrini
Kathryn L. Pellegrini
DPDattatraya Patil
Dattatraya Patil
KDKristen J.S. Douglas
Kristen J.S. Douglas
GLGrace Lee
Grace Lee
KWKathryn Wehrmeyer
Kathryn Wehrmeyer
MSMartin G. Sanda
Martin G. Sanda

1 July 2017 in Journal of Urology
Verified
Journal Article
Closed access
POPadraic G. O’mAlley
Padraic G. O’mAlley
DNDaniel P. Nguyen
Daniel P. Nguyen
BABashir Al Hussein Al Awamlh
Bashir Al Hussein Al Awamlh
GWGuojiao Wu
Guojiao Wu
ITIan M. Thompson
Ian M. Thompson
DSDouglas S. Scherr
Douglas S. Scherr
To our knowledge it is unknown whether urinary biomarkers for prostate cancer have added utility to clinical risk calculators in different racial groups. We examined the utility of urinary biomarkers added to clinical risk calculators for predicting prostate cancer in African American and nonAfrican American men. Demographics, PCPT (Prostate Cancer Prevention Trial) risk scores, data on the biomarkers data PCA3 (prostate cancer antigen 3) and T2ERG (transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog gene fusion), and biopsy pathology features were prospectively collected on 718 men as part of EDRN (Early Detection Research Network). Utility was determined by generating ROC curves and comparing AUC values for the baseline multivariable PCPT model and for models containing biomarker scores. PCA3 and T2ERG added utility for the prediction of prostate cancer and clinically significant prostate cancer when combined with the PCPT Risk Calculator. This utility was seen in nonAfrican American men only for PCA3 (AUC 0.64 increased to 0.75 for prostate cancer and to 0.69-0.77 for clinically significant prostate cancer, both p <0.001) and for T2ERG (AUC 0.64-0.74 for prostate cancer, p <0.001, and 0.69-0.73 for clinically significant prostate cancer, p = 0.029). African American men did not have an added benefit with the addition of biomarkers, including PCA3 (AUC 0.75-0.77, p = 0.64, and 0.65-0.66, p = 0.74) and T2ERG (AUC 0.75-0.74, p = 0.74, and 0.65-0.64, p = 0.88), for prostate cancer and clinically significant prostate cancer, respectively. Limitations include the small number of African American men (72). The post hoc subgroup analysis nature of the study limited findings to being hypothesis generating. As novel biomarkers are discovered, clinical utility should be established across demographically diverse cohorts.

1 November 2022 in Journal of Urology
Verified
Journal Article
Closed access
CFChristopher P. Filson
Christopher P. Filson
KZKehao Zhu
Kehao Zhu
YHYijian Huang
Yijian Huang
YZYingye Zheng
Yingye Zheng
LNLisa F. Newcomb
Lisa F. Newcomb
DLDaniel W. Lin
Daniel W. Lin
Objective: We assessed whether Prostate Health Index (phi) results improve prediction of grade reclassification for men on active surveillance. Methods/Materials: We identified men in Canary Prostate Active Surveillance Study with Grade Group (GG) 1 cancer. Outcome was grade reclassification to GG2+ cancer. We considered decision rules to maximize specificity with sensitivity set at 95%. We derived rules based on clinical data (R1) vs clinical data+phi (R3). We considered an “or”-logic rule combining clinical score and phi (R4), and a “two-step” rule using clinical data followed by risk stratification based on phi (R2). Rules were applied to a validation set, where values of R2 - R4 vs R1 for specificity and sensitivity were evaluated. Results: We included 1532 biopsies (n=610 discovery; n=922 validation) among 1142 men. Grade reclassification was seen in 27% of biopsies (23% discovery, 29% validation). Among discovery set, at 95% sensitivity, R2 yielded highest specificity at 27% vs 17% for R1. In validation set, R3 had best performance vs R1 with Δsensitivity = -4% and Δspecificity = +6%. There was slight improvement for R3 vs R1 for confirmatory biopsy (AUC 0.745 vs R1 0.724, ΔAUC=0.021, 95%CI 0.002–0.041) but not for subsequent biopsies (ΔAUC=-0.012, 95%CI -0.031–0.006). R3 did not have better discrimination vs R1 among the biopsy cohort overall (ΔAUC=0.007, 95%CI -0.007–0.020). Conclusions: Among active surveillance patients, using phi with clinical data modestly improved prediction of grade reclassification on confirmatory biopsy and did not improve prediction on subsequent biopsies.

9 January 2019 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
LWLeslie Wilson
Leslie Wilson
TBTraci M. Blonquist
Traci M. Blonquist
FHFangxin Hong
Fangxin Hong
BHBarbara Halpenny
Barbara Halpenny
SWSeth Wolpin
Seth Wolpin
DBDonna Berry
Donna Berry
The Personal Patient Profile-Prostate (P3P) is a web-based decision support system for men newly diagnosed with localized prostate cancer that has demonstrated efficacy in reducing decisional conflict. Our objective was to estimate willingness-to-pay (WTP) for men’s decisional preparation activities. In a multicenter, randomized trial of P3P, usual care group participants received typical preparation for decision making plus referral to publicly-available, educational websites. Intervention group participants received the same, plus online P3P educational media specific to the user’s personal preferences and values, and a communication coaching component tailored to race\ethnicity, age and language. WTP data were collected one week after physician consultation. An iterative bidding direct contingent valuation survey format was used, randomly assigning participants to high or low starting values (SV). Tobit models were used to explore associations between SV-adjusted WTP and age, education, marital and work-status, insurance, decision-control preference and decision-making stage. Of 392 participants enrolled, 141 P3P and 107 usual care (UC) provided a WTP value. Men were willing to pay a median $25 (IQR $10–100) for P3P in addition to usual care preparation materials. In the final multivariable tobit regression model, SV, marital status, stage of decision making and income were significantly associated with WTP for P3P. Decision control preference was considered marginally significant (p = 0.11). Men were WTP a median $30 (IQR $10–$200) for usual care material alone. In the final multivariable model, SV, education, and stage of decision making were significantly associated with WTP in usual care. WTP was similar for UC and for the addition of P3P to UC decision preparation. The WTP values were associated with demographic and preference variables. Findings can help focus decision support on future patients who would benefit most: those without strong support systems, at earlier stages of decision making, and open to a shared-decision style. NCT NCT01844999 . Registered May 3, 2013.